- Home
- HALO vs CORT Comparison
HALO vs CORT Comparison
Compare HALO & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HALO
- CORT
- Stock Information
- Founded
- HALO 1998
- CORT 1998
- Country
- HALO United States
- CORT United States
- Employees
- HALO N/A
- CORT N/A
- Industry
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- HALO Health Care
- CORT Health Care
- Exchange
- HALO Nasdaq
- CORT Nasdaq
- Market Cap
- HALO 7.6B
- CORT 7.6B
- IPO Year
- HALO N/A
- CORT N/A
- Fundamental
- Price
- HALO $75.81
- CORT $75.18
- Analyst Decision
- HALO Buy
- CORT Strong Buy
- Analyst Count
- HALO 8
- CORT 4
- Target Price
- HALO $70.25
- CORT $139.00
- AVG Volume (30 Days)
- HALO 1.8M
- CORT 675.5K
- Earning Date
- HALO 10-30-2025
- CORT 10-29-2025
- Dividend Yield
- HALO N/A
- CORT N/A
- EPS Growth
- HALO 68.93
- CORT N/A
- EPS
- HALO 4.37
- CORT 1.11
- Revenue
- HALO $1,178,672,000.00
- CORT $716,080,000.00
- Revenue This Year
- HALO $32.57
- CORT $30.62
- Revenue Next Year
- HALO $23.25
- CORT $37.68
- P/E Ratio
- HALO $17.40
- CORT $67.23
- Revenue Growth
- HALO 34.97
- CORT 25.71
- 52 Week Low
- HALO $42.01
- CORT $38.68
- 52 Week High
- HALO $77.60
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- HALO 70.39
- CORT 60.68
- Support Level
- HALO $75.25
- CORT $69.03
- Resistance Level
- HALO $77.60
- CORT $74.79
- Average True Range (ATR)
- HALO 1.67
- CORT 2.69
- MACD
- HALO -0.36
- CORT 0.32
- Stochastic Oscillator
- HALO 70.66
- CORT 95.68
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.